Professor Mariam Jamal-Hanjani has been officially appointed as the new Chief Clinician at Cancer Research UK, marking a significant leadership transition for the world’s leading independent cancer charity. In her new role, Professor Jamal-Hanjani will take on a pivotal responsibility in shaping the organization’s overarching clinical research strategy, guiding clinical trials, and spearheading vital national efforts to improve cancer prevention, diagnosis, and treatment outcomes for patients across the United Kingdom and beyond.
Operating at the very forefront of modern oncology, Professor Jamal-Hanjani brings a wealth of academic and clinical expertise to her new position. Alongside her leadership role at Cancer Research UK, she serves as a Professor of Cancer Genomics and Metastasis at University College London (UCL). She is widely recognized within the international scientific community as a leading authority on how cancer evolves, spreads throughout the body, and develops complex resistance mechanisms against existing therapeutic interventions. Her pioneering scientific investigations have consistently sought to decode the biological intricacies of tumors, shedding light on the molecular pathways that allow cancer to outsmart conventional therapies.
A cornerstone of Professor Jamal-Hanjani’s illustrious research career includes her involvement in major, high-impact studies investigating lung cancer. Through meticulous genomic analysis and clinical observation, her work has helped scientists gain a much deeper understanding of how tumors change and mutate over extended periods of time. Crucially, her research has helped answer fundamental questions regarding why certain forms of cancer become increasingly difficult to treat as they progress. By mapping out the evolutionary trajectory of tumors, her findings help pave the way for the development of more precise, targeted treatments that can adapt to the shifting nature of the disease, ultimately aiming to secure better long-term prognoses and survival rates for patients facing devastating diagnoses.
The appointment has been met with widespread enthusiasm from leadership across the scientific and medical research sectors. Michelle Mitchell, Chief Executive of Cancer Research UK, warmly welcomed Professor Jamal-Hanjani to her new post, highlighting the profound depth of experience she brings to the organization. Praising her exemplary track record, Mitchell noted that the newly appointed Chief Clinician possesses a rare combination of clinical acumen and visionary research leadership.
Reflecting on Professor Jamal-Hanjani’s professional background, Mitchell emphasized her proven ability to lead high-performing research teams capable of delivering radical, groundbreaking insights into the behavior of cancer. These teams have played a crucial role in illuminating the ways tumors grow, spread to secondary sites, resist medical interventions, and occasionally return after periods of remission. Such insights are considered indispensable as the medical community strives to outpace the disease through innovative therapeutic strategies.
Expressing her own thoughts on stepping into the role, Professor Jamal-Hanjani spoke of the profound honor and responsibility associated with the position. She emphasized that Cancer Research UK holds an extraordinary, world-renowned track record of successfully translating rigorous laboratory discoveries into tangible, real-world benefits for patients in clinical settings. Having the opportunity to help shape and guide that critical mission moving forward is something she regards as a profound and humbling privilege.
Furthermore, Professor Jamal-Hanjani underscored her overarching ambition to accelerate the translation of scientific research into superior clinical outcomes for cancer patients. In discussing the structural advantages available within the UK, she specifically highlighted the National Health Service (NHS) as a monumental asset. The unique integration of clinical care and academic research within the NHS provides an exceptional environment for connecting cutting-edge scientific discoveries directly with the patients who need them most, bridging the gap between theoretical medicine and bedside application.
Professor Jamal-Hanjani officially commenced her tenure as Chief Clinician in October 2026. In taking on the mantle, she succeeds Professor Charles Swanton, a distinguished oncologist and researcher who held the position with distinction since 2017. Professor Swanton’s tenure was marked by remarkable advancements in our understanding of tumor heterogeneity and mutagenesis, leaving behind a robust foundation upon which Professor Jamal-Hanjani will now build as she steers Cancer Research UK into its next chapter of clinical innovation and patient advocacy.